Last reviewed · How we verify
AEVI-001
AEVI-001 is a small molecule drug that targets the PI3K/AKT pathway.
AEVI-001 is a small molecule drug that targets the PI3K/AKT pathway. Used for Relapsed or refractory acute lymphoblastic leukemia (ALL).
At a glance
| Generic name | AEVI-001 |
|---|---|
| Also known as | MDGN-001, NFC-1 |
| Sponsor | Aevi Genomic Medicine, LLC, a Cerecor company |
| Drug class | PI3K inhibitor |
| Target | PI3K |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
It works by inhibiting the PI3K/AKT pathway, which is involved in cell growth and survival. This inhibition can lead to the death of cancer cells. AEVI-001 is being investigated as a potential treatment for various types of cancer.
Approved indications
- Relapsed or refractory acute lymphoblastic leukemia (ALL)
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations (PHASE2)
- PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations (PHASE2)
- Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AEVI-001 CI brief — competitive landscape report
- AEVI-001 updates RSS · CI watch RSS
- Aevi Genomic Medicine, LLC, a Cerecor company portfolio CI